

**Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX**


The Eventide Gilead Fund is a diversified mutual fund that seeks to provide long-term capital appreciation. The fund invests in primarily equity securities of companies that we believe demonstrate values and business practices that are ethical, sustainable, and provide an attractive investment opportunity. The fund also invests in securities that have significant near-term appreciation potential.

**TOP HOLDINGS\***

- Macquarie Infrastructure Corp (4.18%)** Aircraft services, liquid storage and marine terminals
- Lear Corp (3.80%)** Advanced automotive electrical systems and seating
- XPO Logistics Inc (3.71%)** Top ten global provider of transportation and logistics solutions
- Lam Research Corp (3.28%)** Supplying wafer fabrication equipment for the semiconductor industry
- AbbVie Inc (3.20%)** Innovation-driven global biopharmaceutical leader
- Lowe's Cos Inc (3.19%)** 1,800 home improvement stores in the U.S., Canada and Mexico
- Five Prime Therapeutics Inc (3.05%)** Screening human proteins to discover and develop novel drugs
- Celgene Corp (2.98%)** Discovery, development and commercialization of life-changing cancer therapies
- KAR Auction Services Inc (2.77%)** Financial and logistical services for the wholesale used car industry
- Mobileye NV (2.65%)** Software for camera-based advanced driver assistance systems

**Growth of \$10,000**


Jul 2008–Sep 2016†



Percent Returns by Year	2009	2010	2011	2012	2013	2014	2015	YTD
■ Eventide Gilead Fund‡	46.08	18.46	0.25	18.15	52.93	17.86	-2.15	1.80
■ Russell Midcap Growth Index	46.29	26.38	-1.65	15.81	35.74	11.90	-0.20	6.84
■ S&P 500 Total Return Index	26.46	15.06	2.11	16.00	32.39	13.69	1.38	7.84

**Fund Returns**

% as of 30 Sep 2016†



Performance is historic and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index and unmanaged index returns do not reflect any fees, expenses or sales charges. To obtain the most recent month-end performance information and a current Eventide Gilead Fund prospectus please call the fund, toll free at 1-877-771-EVEN (3836).

\* Based on percentage of net assets. Holdings can change at any time and should not be considered investment advice.

† These charts compare the Eventide Gilead Fund to index fund performance over the previous periods shown, and since inception. Since inception returns pertain to Class N and are annualized and assume the inception date of 8 July 2008. Performance will differ for other fund classes, based upon fees and commissions. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization. It is not an investment product available for purchase. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. The volatility of the indices may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as the indices listed.

‡ Returns pertain to Class N.

\*\* Aggregate total return, not annualized.


†† Annualized since inception returns assume an inception date of 8 July 2008.

**Class A: ETAGX | Class C: ETCGX | Class I: ETILX | Class N: ETGLX**


**OVERVIEW**

Fund	Nasdaq	Sales Charge*	12b-1 Fees	Total Expenses	Inception Date
Class A	ETAGX	Front-end: 5.75%	0.25%	1.43%	10/28/2009
Class C	ETCGX	None	1.00%	2.18%	10/28/2009
Class I	ETILX	None	0.00%	1.18%	2/2/2010
Class N	ETGLX	None	0.20%	1.38%	7/8/2008

Minimum Investment: \$1,000 or \$100 with AIP (Class A, C, N), \$100,000 (Class I)  
 Net assets: \$1.40 billion



Equity market capitalization: \$15.0B average, \$3.76B median



**Market Risk\*\***

	Std. Dev.	Beta	Alpha	R-Squared
3 Year (Annualized)	16.75%	1.18	-5.58%	58.63%
5 Year (Annualized)	16.77%	1.23	0.50%	66.27%
Inception (Annualized)††	19.89%	1.04	4.49%	69.39%

**MANAGERS**

**Dr. Finny Kuruvillea** has a unique background in healthcare, statistics, and investing. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master's degree in Electrical Engineering and Computer Science from MIT, and a bachelor's degree from Caltech in Chemistry. He completed his residency and fellowship at the Brigham & Women's Hospital and Children's Hospital Boston where he cared for adult and pediatric patients suffering from a variety of hematologic, oncologic, and autoimmune disorders. Subsequently, he was a research fellow at MIT where he designed and implemented statistical algorithms involving logistic regression and pseudo-Bayesian expectation maximization. As an avid proponent of values-based investing, Dr. Kuruvillea has developed standards for selecting ethical companies at the outset of the stock selection process.



**David Barksdale** has a background in software development, engineering and management and is primarily responsible for quantitative research, risk analysis and asset allocation. He holds a bachelor's degree from Caltech in Engineering & Applied Science. By developing and applying novel analytical tools and strategies, Mr. Barksdale works to optimize portfolio returns on a risk-adjusted basis.



\* Other expenses that apply to a continued investment in the fund are described in the Fund's prospectus.

† Companies valued at greater than \$10 billion are Large Cap; those at less than \$1 billion are Small Cap. Portfolio Composition is subject to change at any time, and should not be considered investment advice.

‡ The Fund may not invest 25% or more of its total assets in a particular industry or group of industries. A sector is normally composed of many industry groups. Sector Allocation is subject to change at any time, and should not be considered investment advice.

\*\* Source: Zephyr StyleADVISOR, with Fund returns supplied to Zephyr by Morningstar, Inc.

Standard deviation of return measures the average deviations of a return series from its mean. StyleADVISOR calculates standard deviation as the square root of the squared differences of each monthly return from the mean monthly return over the specified period. Beta is a measure of systematic risk, or the sensitivity of ETGLX to movements in the S&P 500 Index (Index). StyleADVISOR defines Beta as the covariance of ETGLX and Index divided by the variance of the Index. Alpha is the mean of the excess return of ETGLX over beta times the Index. The R-Squared (R<sup>2</sup>) of ETGLX versus the Index is a measure of how closely related the variance of ETGLX returns and the variance of the Index returns are. StyleADVISOR calculates R<sup>2</sup> by squaring the correlation of monthly returns between ETGLX and the Index over the specified period.

†† Annualized since inception market risk details assume inception date of 1 August 2008 and not Class N's actual inception date of 8 July 2008, as only full month data is included in the market risk calculations.

**Mutual Funds involve risk including the possible loss of principal.**

**Past performance does not guarantee future results.** The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund's ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, thus subject to additional risks. Because of ongoing market volatility, Fund performance may be subject to substantial short-term changes.

Investors should consider the Fund's objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the fund's prospectus, which can be obtained at [www.eventidefunds.com](http://www.eventidefunds.com) or by calling 877-771-EVEN (3836). Please read the prospectus carefully before investing. The Fund is distributed by Northern Lights Distributors, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.